MX2013011526A - Derivados de isoxazol utiles como agentes antibacteriales . - Google Patents

Derivados de isoxazol utiles como agentes antibacteriales .

Info

Publication number
MX2013011526A
MX2013011526A MX2013011526A MX2013011526A MX2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A
Authority
MX
Mexico
Prior art keywords
antibacterial agents
derivatives useful
isoxazole derivatives
formula
isoxazole
Prior art date
Application number
MX2013011526A
Other languages
English (en)
Inventor
Matthew F Brown
Jinshan Michael Chen
Michael Melnick
Justin I Montgomery
Usa Reilly
Joseph A Abramite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013011526A publication Critical patent/MX2013011526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida a una nueva clase de derivados de ácido hidroxámico, sus usos como inhibidores de LpxC y, de modo más específico, su uso para tratar infecciones bacteriales.
MX2013011526A 2011-04-08 2012-03-23 Derivados de isoxazol utiles como agentes antibacteriales . MX2013011526A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473540P 2011-04-08 2011-04-08
PCT/IB2012/051406 WO2012137094A1 (en) 2011-04-08 2012-03-23 Isoxazole derivatives useful as antibacterial agents

Publications (1)

Publication Number Publication Date
MX2013011526A true MX2013011526A (es) 2013-12-06

Family

ID=45999906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011526A MX2013011526A (es) 2011-04-08 2012-03-23 Derivados de isoxazol utiles como agentes antibacteriales .

Country Status (14)

Country Link
US (1) US8748466B2 (es)
EP (1) EP2694488B1 (es)
JP (1) JP2014510132A (es)
KR (1) KR20130140868A (es)
CN (1) CN103717582B (es)
AU (1) AU2012238374B2 (es)
CA (1) CA2830920C (es)
DK (1) DK2694488T3 (es)
ES (1) ES2526687T3 (es)
IL (2) IL228799A (es)
MX (1) MX2013011526A (es)
SG (1) SG193367A1 (es)
WO (1) WO2012137094A1 (es)
ZA (1) ZA201306736B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
CA2830866A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
US8748466B2 (en) 2011-04-08 2014-06-10 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9937156B2 (en) * 2013-10-16 2018-04-10 The Board Of Regents Of The University Of Texas System Modulation of MRTF-A activity in pathologic fibrosis and wound healing
MX360983B (es) 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Derivados antibacterianos de 1h-indazol y 1h-indol.
AR099612A1 (es) * 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
JP6514716B2 (ja) * 2014-04-22 2019-05-15 ノバルティス アーゲー ＬｐｘＣ阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
EP3221300B1 (en) 2014-11-19 2019-03-20 Idorsia Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
MY195743A (en) * 2014-12-16 2023-02-08 Novartis Ag Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
US10590498B2 (en) * 2016-05-17 2020-03-17 Lawrence Livermore National Security, Llc Compounds for reactivation of acetylcholinesterase and related compositions methods and systems
AU2017283768B2 (en) * 2016-06-14 2019-05-23 Novartis Ag Crystalline form of (R)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
DE102016113269A1 (de) 2016-07-19 2018-01-25 Osram Opto Semiconductors Gmbh Leuchtvorrichtung für ein mobiles endgerät
TWI604678B (zh) * 2016-09-07 2017-11-01 國立暨南國際大學 Radio transmission system
US10160724B2 (en) * 2016-09-28 2018-12-25 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
US11186548B2 (en) 2017-11-23 2021-11-30 Lawrence Livermore National Security, Llc Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them
US20220002279A1 (en) * 2018-11-21 2022-01-06 Taisho Pharmaceutical Co., Ltd. Novel imidazole derivative
CN111944719B (zh) * 2020-08-14 2022-04-29 暨南大学 一株二恶烷降解菌is20及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
PL194240B1 (pl) 1998-02-07 2007-05-31 British Biotech Pharm Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy
GB9925470D0 (en) 1999-10-27 1999-12-29 Smithkline Beecham Plc Novel compounds
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
CA2512582C (en) 2003-01-08 2014-07-08 University Of Washington Antibacterial agents
GB0302431D0 (en) 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
WO2006118155A1 (ja) 2005-04-27 2006-11-09 Ishihara Sangyo Kaisha, Ltd. ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
CA2634005C (en) 2005-12-15 2012-01-03 Vicuron Pharmaceuticals Inc. N-hydroxyamide derivatives possessing antibacterial activity
JP2009526832A (ja) * 2006-02-14 2009-07-23 ファイザー・プロダクツ・インク 抗菌剤としてのベンゾオキサジノンおよびベンゾオキサゼピノンオキサゾリジノン
US20080085893A1 (en) 2006-10-06 2008-04-10 Shyh-Ming Yang Matrix metalloprotease inhibitors
CN101016270B (zh) * 2006-12-30 2012-05-09 天津药物研究院 取代的哌嗪基苯基异噁唑啉衍生物及其用途
WO2009008905A1 (en) 2007-02-01 2009-01-15 Panthera Biopharma, Llc. Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
JP5227304B2 (ja) 2007-02-28 2013-07-03 大正製薬株式会社 新規なヒドロキサム酸誘導体
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2010017060A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
CA2735929C (en) * 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
US8748466B2 (en) 2011-04-08 2014-06-10 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CA2830866A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Also Published As

Publication number Publication date
CN103717582A (zh) 2014-04-09
AU2012238374A1 (en) 2013-09-26
CA2830920C (en) 2015-07-14
IL228799A (en) 2015-08-31
CA2830920A1 (en) 2012-10-11
IL228799A0 (en) 2013-12-31
DK2694488T3 (en) 2014-12-15
ZA201306736B (en) 2014-11-26
AU2012238374B2 (en) 2015-04-02
WO2012137094A1 (en) 2012-10-11
US20140024690A1 (en) 2014-01-23
ES2526687T3 (es) 2015-01-14
EP2694488A1 (en) 2014-02-12
US8748466B2 (en) 2014-06-10
IL240078A0 (en) 2015-08-31
JP2014510132A (ja) 2014-04-24
SG193367A1 (en) 2013-10-30
KR20130140868A (ko) 2013-12-24
CN103717582B (zh) 2015-09-30
EP2694488B1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
MX341977B (es) Derivados de fluoro-piridinona utiles como agentes antibacterianos.
WO2011045703A3 (en) C-linked hydroxamic acid derivatives useful as antibacterial agents
MX2013011432A (es) Derivados de imidazol, pirazol, y triazol utiles como agentes antibacterianos.
PH12016502436A1 (en) Anti-infective compounds
MX2013005994A (es) Monobactamas.
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
PH12014502224A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
EA201390274A1 (ru) Борсодержащие малые молекулы
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014CN04558A (es)
EA201492210A1 (ru) Соединения, ингибирующие активность катехол-o-метилтрансферазы
MX2017009094A (es) Derivado de polimixina y usos del mismo.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MY189098A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
MX2015001834A (es) Nuevos compuestos antibacterianos.
MX2015001835A (es) Nuevos compuestos antibacterianos.
EA201300092A1 (ru) Замещенные производные оксадиазола
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
GEP20156264B (en) Use of nifuratel to treat infections caused by clostridium species
CY1115821T1 (el) Παραγωγα ν-συνδεδεμενου υδροξαμικου οξεος χρησιμα ως αντιβακτηριακοι παραγοντες
PL398895A1 (pl) Zastosowanie styrylochinolin do wytwarzania srodków antybakteryjnych

Legal Events

Date Code Title Description
FA Abandonment or withdrawal